Capital Investment Advisors LLC Sells 26,437 Shares of Pfizer Inc. $PFE

Capital Investment Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 5.8% in the 4th quarter, Holdings Channel reports. The fund owned 432,413 shares of the biopharmaceutical company’s stock after selling 26,437 shares during the quarter. Capital Investment Advisors LLC’s holdings in Pfizer were worth $10,767,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new stake in Pfizer during the second quarter worth about $2,270,157,000. Franklin Resources Inc. boosted its holdings in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Pfizer by 203.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after purchasing an additional 6,045,763 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after buying an additional 5,978,927 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in Pfizer by 43.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after buying an additional 5,662,309 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. HSBC upped their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Morgan Stanley set a $27.00 price objective on shares of Pfizer and gave the stock a “positive” rating in a report on Tuesday, March 17th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Finally, Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.19.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Pfizer Stock Performance

Shares of PFE stock opened at $27.03 on Friday. The company has a market capitalization of $153.70 billion, a P/E ratio of 19.88 and a beta of 0.47. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a 50 day moving average price of $26.84 and a two-hundred day moving average price of $25.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the business earned $0.63 earnings per share. The business’s revenue was down 1.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.